BR112019000540A2 - método para produzir uma forma polimórfica de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida - Google Patents

método para produzir uma forma polimórfica de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida

Info

Publication number
BR112019000540A2
BR112019000540A2 BR112019000540-4A BR112019000540A BR112019000540A2 BR 112019000540 A2 BR112019000540 A2 BR 112019000540A2 BR 112019000540 A BR112019000540 A BR 112019000540A BR 112019000540 A2 BR112019000540 A2 BR 112019000540A2
Authority
BR
Brazil
Prior art keywords
cyanobenzoyl
pyrazol
cyclopropyl
amino
methylbenzamide
Prior art date
Application number
BR112019000540-4A
Other languages
English (en)
Inventor
Suleiman Osama
Romero Perez Lucia
Stephan Harlacher Cornelius
Jones Stewart
Original Assignee
Mereo Biopharma 1 Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 1 Limited filed Critical Mereo Biopharma 1 Limited
Publication of BR112019000540A2 publication Critical patent/BR112019000540A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se a um processo para a preparação da forma b de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida. também é descrita aqui a forma b de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida, ou suas composições farmacêuticas, obteníveis pelo processo descrito aqui.
BR112019000540-4A 2016-07-14 2017-07-13 método para produzir uma forma polimórfica de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida BR112019000540A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1612238.4 2016-07-14
GBGB1612238.4A GB201612238D0 (en) 2016-07-14 2016-07-14 Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-Yl]-n-cyclopropyl-4-methylbenzamide
PCT/GB2017/052055 WO2018011578A1 (en) 2016-07-14 2017-07-13 Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide

Publications (1)

Publication Number Publication Date
BR112019000540A2 true BR112019000540A2 (pt) 2019-04-24

Family

ID=56890595

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019000540-4A BR112019000540A2 (pt) 2016-07-14 2017-07-13 método para produzir uma forma polimórfica de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida

Country Status (19)

Country Link
US (1) US10995071B2 (pt)
EP (1) EP3484853B9 (pt)
JP (1) JP7094020B2 (pt)
KR (1) KR102460533B1 (pt)
CN (1) CN109415325B (pt)
AU (1) AU2017294642B2 (pt)
BR (1) BR112019000540A2 (pt)
CA (1) CA3030617C (pt)
DK (1) DK3484853T5 (pt)
ES (1) ES2879608T3 (pt)
GB (1) GB201612238D0 (pt)
HU (1) HUE054686T2 (pt)
IL (1) IL263900B (pt)
MX (1) MX2019000384A (pt)
PL (1) PL3484853T3 (pt)
PT (1) PT3484853T (pt)
RU (1) RU2765719C2 (pt)
SG (1) SG11201811517SA (pt)
WO (1) WO2018011578A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329065A1 (en) * 1998-05-05 1999-11-11 Francisco Xavier Talamas Pyrazole derivatives as p-38 map kinase inhibitors
NZ544230A (en) 2003-06-26 2009-07-31 Novartis Ag 5-Membered heterocycle-based P38 kinase inhibitors
PL2827860T3 (pl) 2012-03-20 2017-09-29 Mereo Biopharma 1 Limited Zastosowanie pochodnej pirazolowej w leczeniu nagłych zaostrzeń przewlekłej obturacyjnej choroby płuc
JP6741773B2 (ja) 2016-03-08 2020-08-19 メレオ バイオファーマ １ リミテッド 炎症状態の急性増悪の治療のための投与レジメン
JP6741774B2 (ja) 2016-03-08 2020-08-19 メレオ バイオファーマ １ リミテッド 慢性閉塞性肺疾患の急性増悪の治療のための投与レジメン

Also Published As

Publication number Publication date
DK3484853T3 (da) 2021-05-25
KR102460533B1 (ko) 2022-10-31
PL3484853T3 (pl) 2021-11-02
SG11201811517SA (en) 2019-01-30
RU2019103879A3 (pt) 2020-08-14
EP3484853A1 (en) 2019-05-22
DK3484853T5 (da) 2021-09-06
GB201612238D0 (en) 2016-08-31
AU2017294642A1 (en) 2019-01-17
PT3484853T (pt) 2021-05-25
CN109415325A (zh) 2019-03-01
IL263900A (en) 2019-01-31
RU2765719C2 (ru) 2022-02-02
EP3484853B9 (en) 2021-07-28
MX2019000384A (es) 2019-05-23
IL263900B (en) 2022-04-01
ES2879608T3 (es) 2021-11-22
RU2019103879A (ru) 2020-08-14
CA3030617A1 (en) 2018-01-18
CN109415325B (zh) 2022-04-01
HUE054686T2 (hu) 2021-09-28
WO2018011578A1 (en) 2018-01-18
US10995071B2 (en) 2021-05-04
US20190315694A1 (en) 2019-10-17
KR20190027819A (ko) 2019-03-15
AU2017294642B2 (en) 2021-03-04
EP3484853B1 (en) 2021-04-21
JP2019521133A (ja) 2019-07-25
CA3030617C (en) 2024-02-20
JP7094020B2 (ja) 2022-07-01

Similar Documents

Publication Publication Date Title
CL2019003154A1 (es) Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)
IL258324B (en) Methods to create various cannabis product compounds
BR112017023950A2 (pt) processo para a preparação de limonen-4-ol
EA201890752A1 (ru) Способ получения противогрибковых соединений
EA201992873A1 (ru) Получение фосфатных производных
EP3589623C0 (en) PRODUCTION OF 2,5-FURANDIC ACID
BR112017006116A2 (pt) processos de preparação de compostos e compostos
WO2015121379A3 (en) Process for producing vanillin
ZA201803510B (en) Process for the production of 2,5-furandicarboxylic acid (fdca)
PH12019502093A1 (en) Novel ester compounds, method for the production thereof and use thereof
IT201600105178A1 (it) Procedimento per la produzione di dieni
EA201892515A1 (ru) Стероидные 6,7-бета-эпоксиды в качестве интермедиатов
BR112017019850A2 (pt) ?processo melhorado para a preparação de apremilast?
CL2018002756A1 (es) Un proceso mejorado para la preparación de tartrato de butorfanol.
BR112016025024A2 (pt) ?processo para preparar compostos ceto, e, uso de farnesil acetona?
MA39480A (fr) Nouveau procédé pour la préparation de prostaglandines de haute pureté
BR112017024785A2 (pt) Forma cristalina do composto (s) -3 -{4 -[5 -(2 - ciclopentil -6 -metoxi -piridin -4 -il) -[1,2,4] oxadiazol -3 -il] -2 -etil -6 -metil -fenoxi} -propano -1,2 -diol
BR112017025873A2 (pt) método para revestir a cabeça de um pirulito com um material de revestimento
MX2019004024A (es) Metodo para preparar acetofenonas sustituidas con ciclopropilo.
IL268465B (en) A method for the production of iodine-modified organic compounds in one vessel
BR112019000460A2 (pt) método para produzir uma forma polimórfica de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il] -n-ciclopropil-4-metilbenzamida
MA51339A (fr) Procédé de préparation de composés pyrimidinyl-4-aminopyrazole
BR112016023767A2 (pt) forma sólida, composição farmacêutica, compostos, métodos, composições e utilizações
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
BR112019000540A2 (pt) método para produzir uma forma polimórfica de 3-[5-amino-4-(3-cianobenzoil)-pirazol-1-il]-n-ciclopropil-4-metilbenzamida

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]